M
Michal Mego
Researcher at Comenius University in Bratislava
Publications - 211
Citations - 3891
Michal Mego is an academic researcher from Comenius University in Bratislava. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 30, co-authored 170 publications receiving 3043 citations. Previous affiliations of Michal Mego include Thomas Jefferson University & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Molecular mechanisms of metastasis in breast cancer--clinical applications
TL;DR: Interruption of the metastatic cascade via the targeting of CTCs might be a promising therapeutic strategy to evaluate targeted therapies based on the genomic profiling of C TCs and to improve the clinical management of patients by personalized therapy.
Journal ArticleDOI
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
Mario Giuliano,Mario Giuliano,Mario Giuliano,Antonio Giordano,Antonio Giordano,S. Jackson,Kenneth R. Hess,Ugo De Giorgi,Michal Mego,Michal Mego,Beverly Carol Handy,Naoto T. Ueno,Ricardo H. Alvarez,Michelino De Laurentiis,Sabino De Placido,Vicente Valero,Gabriel N. Hortobagyi,James M. Reuben,Massimo Cristofanilli +18 more
TL;DR: This analysis suggests that the prognostic information provided by CTC count may be useful in patient stratifications and therapeutic selection, particularly in the group with positive CTCs, in which various therapeutic choices may procure differential palliative benefit.
Journal ArticleDOI
Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
Antonio Giordano,Hui Gao,Simone Anfossi,Evan N. Cohen,Michal Mego,Bang Ning Lee,S Tin,Michele De Laurentiis,Charla A. Parker,Ricardo H. Alvarez,Vicente Valero,Naoto T. Ueno,Sabino De Placido,Sendurai A. Mani,Francisco J. Esteva,Massimo Cristofanilli,James M. Reuben +16 more
TL;DR: The authors' data indicate that patients with HER2+ MBCs have EMT-CTCs, and an enrichment of CSCs was found in CD326−CD45− cells.
Journal ArticleDOI
Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study.
Michal Mego,Jozef Chovanec,Iveta Vochyanova-Andrezalova,Peter Konkolovsky,Milada Mikulova,Maria Reckova,Vera Miskovska,Branislav Bystricky,Juraj Beniak,Lenka Medvecova,Adela Lagin,Daniela Svetlovska,Stanislav Spanik,Vladimir Zajac,Jozef Mardiak,Lubos Drgona +15 more
TL;DR: Administration of probiotics in patients with colorectal cancer treated with irinotecan-based chemotherapy is safe and could lead to a reduction in the incidence and severity of gastrointestinal toxicity.
Journal ArticleDOI
Expression of Epithelial-Mesenchymal Transition-Inducing Transcription Factors in Primary Breast Cancer: The Effect of Neoadjuvant Therapy
Michal Mego,Sendurai A. Mani,Bang Ning Lee,Changping Li,Kurt W. Evans,Evan N. Cohen,Hui Gao,S. Jackson,Antonio Giordano,Gabriel N. Hortobagyi,Massimo Cristofanilli,Anthony Lucci,James M. Reuben +12 more
TL;DR: It is demonstrated that C TCs with EMT phenotype may occur in the peripheral circulation of patients with PBC and that NAT is unable to eliminate CTCs undergoing EMT.